Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119884) titled 'Benmelstobart Plus TPF Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase 2 Trial' on March 4.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Condition:
Nasopharyngeal Carcinoma
Intervention:
single-arm:(1) Induction chemotherapy plus immunotherapy: Benmelstobart plus docetaxel, cisplatin, and 5-fluorouracil (docetaxel 60 mg/m2 on Day 1
cisplatin 60 mg/m2 on Day 1
fluorouracil 600 mg/m2 on Days 1-5
benmelstobart 1200 mg per dose on Day 1). Induction chemoimmunotherapy will be administered every 3 week...